Shed Secures Exclusive Telehealth Rights for ROXUS®, Revolutionizing ED Treatment in the U.S.

Shed Secures Exclusive Rights to ROXUS® for U.S. Telehealth

Shed, a prominent telehealth platform based in Salt Lake City, announced a significant milestone by securing exclusive rights to provide ROXUS®, a rapid-acting intranasal treatment for erectile dysfunction (ED) directly to U.S. consumers. This innovative treatment, developed by LTR Pharma, boasts a unique delivery method and is set to become available exclusively through Mavrox, Shed's men's health platform.

What is ROXUS®?

ROXUS® represents a groundbreaking shift in the approach to treating erectile dysfunction. Unlike traditional oral PDE5 inhibitors, which can take longer to take effect, ROXUS® utilizes an intranasal delivery system designed for rapid onset of action—approximately five minutes post-administration. This prompt response time positions ROXUS® as a game-changing alternative for individuals seeking effective and immediate solutions for ED.

A Partnership for Innovation

Shed's CEO, Morley Baker, highlighted the importance of this partnership, stating, "Erectile dysfunction remains one of the largest and most underserved categories in men's health. ROXUS® has the potential to fundamentally change the patient experience through its rapid onset and convenient intranasal delivery."

The exclusivity of this agreement is pivotal in strengthening Shed's commitment to leadership in the men's health sector. The company is poised to provide comprehensive care across various health aspects, including hormone optimization, sexual health, weight management, and longevity. Baker expressed enthusiasm about introducing this first-of-its-kind ED solution to the market, claiming it aligns perfectly with Shed’s broader strategy of delivering innovative healthcare solutions through a modern telehealth framework.

Access and Availability

ROXUS® will be accessible through personalized U.S. telehealth pathways, facilitated by LTR Pharma's partnered pharmacies. This arrangement is set to streamline the process for patients, making it easier to access this transformative treatment upon the completion of necessary readiness activities for commercial launch.

This collaboration reflects a shared ambition between Shed and LTR Pharma to enhance patient access rapidly. Baker noted, "This partnership allows us to combine a groundbreaking product with a proven digital healthcare platform capable of reaching patients at scale. We believe ROXUS® has the potential to become a category-defining treatment in men's health."

As for timing, the official launch date will be announced once final preparations are completed.

About Shed

Shed stands out as a telehealth leader dedicated to fostering long-term wellness in individuals through tailored, clinically-directed care. By integrating licensed healthcare professionals with evidence-based treatments and supportive technology, Shed offers holistic solutions across various health domains including weight management, metabolic health, sexual wellness, dermatology, and preventative care. With its innovative care model, Shed strives to improve access and adherence while empowering patients to achieve meaningful health outcomes, regardless of location within the United States.

About Mavrox

Mavrox, Shed's men’s health platform, specializes in providing technology-enabled, personalized healthcare solutions focusing on sexual health, hormone optimization, weight management, and longevity. Through its network of licensed providers and innovative treatment methods, Mavrox delivers seamless telehealth experiences to help men access the care they need easily. With the exclusive U.S. telehealth offering of ROXUS®, Mavrox is set to redefine how men approach erectile dysfunction treatment.

About ROXUS®

Developed by LTR Pharma, ROXUS® is a personalized medicine specifically designed for erectile dysfunction, making use of a rapid-acting intranasal system that takes effect in about five minutes. This novel therapy offers a compelling alternative to conventional oral ED medications.

For more information about Shed and Mavrox and their respective services, visit their websites. Stay tuned for the upcoming commercial launch of ROXUS®.